NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients, has announced the approval of inducement share options. The Compensation Committee granted options for 97,600 ordinary shares to two non-executive new hires at an exercise price of $17.82 per share. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments. These grants were made under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma (Nasdaq: NAMS), un'azienda biopharmaceutical di fase avanzata focalizzata sullo sviluppo di farmaci orali non statinici per pazienti affetti da malattie cardiovascolari, ha annunciato l'approvazione di opzioni di azioni di incentivo. Il Comitato per la Compensazione ha concesso opzioni per 97.600 azioni ordinarie a due nuovi assunti non esecutivi a un prezzo di esercizio di $17,82 per azione. Le opzioni matureranno nell'arco di quattro anni, con 25% che maturerà dopo un anno e il restante saldo che maturerà in 36 rate mensili. Questi conferimenti sono stati effettuati nell'ambito del Piano di Incentivo 2024 in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
NewAmsterdam Pharma (Nasdaq: NAMS), una compañía biofarmacéutica en etapa avanzada centrada en el desarrollo de medicamentos orales no estatínicos para pacientes con enfermedades cardiovasculares, ha anunciado la aprobación de opciones de acciones de incentivo. El Comité de Compensación otorgó opciones para 97,600 acciones ordinarias a dos nuevas contrataciones no ejecutivas a un precio de ejercicio de $17.82 por acción. Las opciones se liberarán a lo largo de cuatro años, con 25% que se liberará después de un año y el saldo restante que se liberará en 36 cuotas mensuales. Estos otorgamientos se realizaron bajo el Plan de Incentivo 2024 de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
NewAmsterdam Pharma (Nasdaq: NAMS)는 심혈관 질환 환자를 위한 경구 비스타틴 약물 개발에 중점을 둔 후기 단계 임상 생물 제약 회사로서, 유인 주식 옵션 승인을 발표했습니다. 보상 위원회는 두 명의 비임원 신입 직원에게 97,600주 일반주식에 대한 옵션을 $17.82의 행사 가격으로 부여했습니다. 옵션은 4년에 걸쳐 발생하며, 25%는 1년 후에 발생하고 나머지 잔액은 36개월 할부로 발생합니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 2024 유인 계획에 따라 이루어졌습니다.
NewAmsterdam Pharma (Nasdaq: NAMS), une société biopharmaceutique en phase avancée spécialisée dans le développement de médicaments oraux non statinés pour les patients atteints de maladies cardiovasculaires, a annoncé l'approbation d'options d'actions d'incitation. Le Comité de Rémunération a accordé des options pour 97 600 actions ordinaires à deux nouvelles recrues non exécutives à un prix d'exercice de 17,82 $ par action. Les options seront acquises sur quatre ans, avec 25% acquises après un an, et le solde restant sera acquis en 36 versements mensuels. Ces attributions ont été faites dans le cadre du Plan d'Incentive 2024 conformément à la Règle de Cotation Nasdaq 5635(c)(4).
NewAmsterdam Pharma (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung von oralen, nicht-statinischen Medikamenten für Patienten mit Herz-Kreislauf-Erkrankungen konzentriert, hat die Genehmigung von Anreiz-Aktienoptionen bekannt gegeben. Der Vergütungsausschuss hat Optionen für 97.600 ordentliche Aktien an zwei neue nicht-executive Mitarbeiter zu einem Ausübungspreis von $17,82 pro Aktie ausgegeben. Die Optionen werden über vier Jahre ausgegeben, wobei 25% nach einem Jahr und der verbleibende Betrag in 36 monatlichen Raten fällig wird. Diese Zuwendungen wurden im Rahmen des Anreizplans 2024 gemäß der Nasdaq Listungsregel 5635(c)(4) gemacht.
- None.
- None.
NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 97,600 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
FAQ
How many shares were included in NewAmsterdam Pharma's (NAMS) November 2024 inducement grants?
What is the exercise price for NewAmsterdam Pharma's (NAMS) November 2024 inducement share options?
What is the vesting schedule for NewAmsterdam Pharma's (NAMS) November 2024 inducement grants?
